Clinical Trials

Date: 2016-02-13

Type of information: Publication of results in a medical journal

phase: 2

Announcement: publication of results in The Lancet

Company: Novo Nordisk (Denmark)

Product: liraglutide

Action mechanism: Glucagon-like Peptide 1 (GLP-1) analogue. Glucagon-like peptide-1 (GLP-1) analogues are able to reduce hepatic steatosis, concentrations of liver enzymes, and insulin resistance in murine models of fatty liver disease.

Disease: NASH (non-alcoholic steatohepatitis)

Therapeutic area: Hepatic diseases - Liver diseases

Country: UK

Trial details: The purpose of the LEAN (Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis ) study is to investigate whether 48 weeks treatment with once-daily injections of liraglutide improves liver disease (liver fat, inflammation and scarring) and related metabolic parameters in overweight patients with nonalcoholic steatohepatitis, enough to warrant further investigation. (NCT01237119)

Latest news:

• • On February 13, 2016, results of the LEAN (Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis ) study have been published in The Lancet. This phase 2 trial was conducted to assess subcutaneous injections of liraglutide (1·8 mg daily) compared with placebo for patients who are overweight and show clinical evidence of non-alcoholic steatohepatitis. The study showed that liraglutide was safe, well tolerated, and led to histological resolution of non-alcoholic steatohepatitis.

 

Is general: Yes